MENVEO

MENVEO [Meningococcal (Groups A, C, Y, and W-135) OligosaccharideDiphtheria CRM197 Conjugate Vaccine.Menveo is a vaccine designed to protect against meningococcal disease, a serious bacterial infection caused by Neisseria meningitidis. This infection can lead to meningitis, which is the inflammation of the protective membranes covering the brain and spinal cord, as well as septicemia, a life-threatening bloodstream infection. Meningococcal disease can progress rapidly and is potentially fatal, making vaccination crucial, especially for those at higher risk.

How It Works

Menveo is a conjugate vaccine that targets four of the most common serogroups of Neisseria meningitidis—A, C, W, and Y. The vaccine contains inactivated bacterial polysaccharides linked to a protein carrier, which enhances the immune response. This helps the immune system recognize and combat the bacteria if exposed in the future, providing immunity against these specific strains.

Administration

• Dosage: Menveo is typically administered as a single dose, with additional doses or boosters recommended in certain situations.
• Schedule:

Primary:

In individuals aged 2 through 55 years, administer as a single dose.(in India as per IAP)

Primary Vaccination for Other countries(NOT INDIA)

• In children initiating vaccination at 2 months of age, administer as a

4-dose series at 2, 4, 6, and 12 months of age. (2.4)

• In children initiating vaccination at 7 months through 23 months of age,

administer as a 2-dose series with the second dose administered in the

second year of life and at least 3 months after the first dose. (2.4

Booster Vaccination

• A single booster dose of MENVEO may be administered to individuals

aged 15 through 55 years who are at continued risk for meningococcal

disease if at least 4 years have elapsed since a prior dose of a

meningococcal (serogroups A, C, Y, W-135) conjugate vaccine. (2.4)

• Administration Method: Given as an intramuscular injection, usually in the upper arm (deltoid muscle).

Side Effects

Common side effects may include:

• Pain, redness, or swelling at the injection site
• Headache
• Fatigue
• Mild fever
• Nausea

Severe reactions are rare.

Pregnancy and Lactation

• Pregnancy: Menveo can be administered during pregnancy if there is a significant risk of exposure to meningococcal disease. Consultation with a healthcare provider is recommended.
• Lactation: Safe for breastfeeding mothers.

Age Group

• Minimum Age: Approved for use in infants starting at 2 years.
• Upper Age Limit: Typically administered from 2 yrs up to 55 years old, though it can be given to older adults in certain circumstances.

Contraindications

• Allergic Reactions: Not recommended for individuals with severe allergies to any component of the vaccine or to a previous dose of a meningococcal vaccine.
• Severe Illness: Vaccination should be postponed in cases of acute, severe febrile illness.

Nature of Antigen

• Nature of Antigen: Menveo contains inactivated bacterial polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, conjugated to a protein carrier.

Vaccine Type

• Type: Menveo is a quadrivalent conjugate vaccine, meaning it protects against four different serogroups (A, C, W, Y) of the meningococcal bacteria.

Origin and Manufacturer

• Origin: Menveo is an imported vaccine.
• Manufacturer: The vaccine is produced by GlaxoSmithKline (GSK), a global healthcare company.
• Introduction Year: Menveo was introduced in 2010.

Menveo is a crucial vaccine for preventing meningococcal disease, particularly for adolescents, travelers, military personnel, and individuals at high risk. Developed and produced by GlaxoSmithKline, Menveo provides comprehensive protection against four major strains of meningococcal bacteria. Always consult healthcare providers for detailed vaccination schedules and personalized advice.